"We are honored and excited to have Jon Saxe join our board," said Evan Unger MD, President and CEO of NuvOx. "His broad knowledge of the industry and years of experience both as an executive and in corporate governance will serve NuvOx well as it continues to grow in the coming years. The other members of the board and I are very much looking forward to working with him." Click here to read more.
top of page
Search
Recent Posts
See AllTucson, AZ, January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” Evan Unger, MD, President and CE
Tucson, AZ, USA, October 31, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role,
Tucson, AZ, September 28th, 2023 NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the Pepperdine Graziadio Business School's sixth annual Most Funda
bottom of page